PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|June 2, 2016
- Pharmaceutical Technology-06-02-2016
- Volume 40
- Issue 6
Acoustic Separator Streamlines Clarifications
The Cadence Acoustic Separator (CAS) from Pall Life Sciences enables the purification of bioprocesses fluids without the use of primary depth filters or centrifuges.
The Cadence Acoustic Separator (CAS) from Pall Life Sciences enables the purification of bioprocesses fluids without the use of primary depth filters or centrifuges. CAS was developed by FloDesign Sonics and is licensed by Pall. CAS’s acoustic wave separation (AWS) technology applies acoustic forces across a countercurrent flow of bioprocess fluid to generate three-dimensional standing waves that trap cells in their nodes. The cells in the bioprocess fluid will agglomerate and eventually sediment as it loses its buoyancy.
The CAS does not cause any significant increase in temperature or damage to cells or proteins. The CAS system allows for the reduction of 75% of the filtration area and associated buffer volume requirements. AWS technology is applicable for the clarification of biologic products, including recombinant therapeutic proteins and monoclonal antibodies. In addition, the CAS is a single-use clarification system that enables continuous processing.
Articles in this issue
over 10 years ago
Modern Manufacturing Comes of Ageover 10 years ago
Examining Blow-Fill-Seal Technology for Aseptic Processesover 10 years ago
Demonstrating a State of Controlover 10 years ago
PAT: “Gateway Drug” to the 21st Century for the Pharma Industryover 10 years ago
Watch Out for the Hangoverover 10 years ago
Deciding When To Use Modular Constructionover 10 years ago
Integrating Single-Use Systems in Pharma Manufacturingover 10 years ago
Steps Closer to the Adoption of Continuous Processingover 10 years ago
Industry Moves Closer to Continuous ManufacturingRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Symptomatic Dermographism: Novartis Lands Remibrutinib Label Expansion
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5